Royal Bank of Canada
SGMO

Royal Bank of Canada’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Royal Bank of Canada’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Buy
4,519
+414
+10% +$165 ﹤0.01% 6945
2025
Q4 		$1K Sell
4,105
-520,903
-99% -$276K ﹤0.01% 7042
2025
Q3 		$353K Buy
525,008
+3,485
+0.7% +$1.88K ﹤0.01% 4731
2025
Q2 		$282K Buy
521,523
+516,517
+10,318% +$307K ﹤0.01% 4906
2025
Q1 		$3K Buy
5,006
+1,354
+37% +$1.43K ﹤0.01% 6524
2024
Q4 		$4K Sell
3,652
-189
-5% -$346 ﹤0.01% 6600
2024
Q3 		$4K Sell
3,841
-9,253
-71% -$6.78K ﹤0.01% 6553
2024
Q2 		$4K Buy
13,094
+7,017
+115% +$3.79K ﹤0.01% 6613
2024
Q1 		$5K Sell
6,077
-51,174
-89% -$37.1K ﹤0.01% 6462
2023
Q4 		$32K Sell
57,251
-80,806
-59% -$37.3K ﹤0.01% 6169
2023
Q3 		$84K Sell
138,057
-89,665
-39% -$96K ﹤0.01% 5500
2023
Q2 		$296K Buy
227,722
+96,068
+73% +$131K ﹤0.01% 4402
2023
Q1 		$232K Buy
131,654
+94,279
+252% +$269K ﹤0.01% 4496
2022
Q4 		$118K Buy
37,375
+8,244
+28% +$32K ﹤0.01% 5323
2022
Q3 		$144K Buy
29,131
+2,937
+11% +$15.1K ﹤0.01% 5041
2022
Q2 		$109K Sell
26,194
-6,754
-20% -$29.2K ﹤0.01% 5274
2022
Q1 		$190K Sell
32,948
-16,863
-34% -$100K ﹤0.01% 5137
2021
Q4 		$374K Buy
49,811
+8,104
+19% +$70.4K ﹤0.01% 4735
2021
Q3 		$375K Buy
41,707
+645
+2% +$6.38K ﹤0.01% 4588
2021
Q2 		$492K Buy
41,062
+6,895
+20% +$78.1K ﹤0.01% 4300
2021
Q1 		$429K Buy
34,167
+3,042
+10% +$41K ﹤0.01% 4318
2020
Q4 		$485K Buy
31,125
+15,010
+93% +$176K ﹤0.01% 4169
2020
Q3 		$152K Buy
16,115
+5,276
+49% +$57.1K ﹤0.01% 4724
2020
Q2 		$97K Buy
10,839
+385
+4% +$3.57K ﹤0.01% 4862
2020
Q1 		$67K Sell
10,454
-22,760
-69% -$169K ﹤0.01% 5005
2019
Q4 		$278K Buy
33,214
+6,339
+24% +$58.3K ﹤0.01% 4405
2019
Q3 		$243K Sell
26,875
-1,176
-4% -$13.2K ﹤0.01% 4327
2019
Q2 		$302K Sell
28,051
-5,780
-17% -$61.5K ﹤0.01% 4202
2019
Q1 		$322K Buy
33,831
+3,450
+11% +$35.2K ﹤0.01% 4052
2018
Q4 		$350K Buy
30,381
+361
+1% +$4.49K ﹤0.01% 3966
2018
Q3 		$508K Buy
30,020
+3,615
+14% +$54.9K ﹤0.01% 3899
2018
Q2 		$374K Buy
26,405
+276
+1% +$4.58K ﹤0.01% 4018
2018
Q1 		$496K Sell
26,129
-16,258
-38% -$348K ﹤0.01% 3717
2017
Q4 		$695K Buy
42,387
+30,915
+269% +$460K ﹤0.01% 3534
2017
Q3 		$171K Buy
11,472
+7,589
+195% +$83.9K ﹤0.01% 4627
2017
Q2 		$34K Sell
3,883
-2,057
-35% -$13.2K ﹤0.01% 5305
2017
Q1 		$30K Sell
5,940
-2,171
-27% -$8.71K ﹤0.01% 5417
2016
Q4 		$25K Sell
8,111
-11,549
-59% -$42.1K ﹤0.01% 5649
2016
Q3 		$91K Sell
19,660
-4,160
-17% -$21.2K ﹤0.01% 4860
2016
Q2 		$138K Hold
23,820
– – ﹤0.01% 4626
2016
Q1 		$144K Sell
23,820
-11,736
-33% -$70.5K ﹤0.01% 4573
2015
Q4 		$325K Buy
35,556
+15,609
+78% +$120K ﹤0.01% 4164
2015
Q3 		$113K Buy
19,947
+8,247
+70% +$68K ﹤0.01% 4708
2015
Q2 		$130K Buy
11,700
+1,000
+9% +$12.9K ﹤0.01% 4676
2015
Q1 		$168K Sell
10,700
-4,800
-31% -$74.3K ﹤0.01% 4333
2014
Q4 		$236K Hold
15,500
– – ﹤0.01% 4227
2014
Q3 		$167K Sell
15,500
-5,000
-24% -$65.3K ﹤0.01% 4304
2014
Q2 		$313K Sell
20,500
-20
-0.1% -$288 ﹤0.01% 3835
2014
Q1 		$370K Sell
20,520
-4,500
-18% -$86.7K ﹤0.01% 3586
2013
Q4 		$347K Sell
25,020
-875
-3% -$10.1K ﹤0.01% 3697
2013
Q3 		$271K Buy
25,895
+540
+2% +$5.36K ﹤0.01% 3865
2013
Q2 		$198K Buy
+25,355
New +$221K ﹤0.01% 3898

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Royal Bank of Canada's SGMO Position: Q1 2026 in Review

Royal Bank of Canada increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 10% in Q1 2026, buying an estimated $165 and bringing the position to 4,519 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6945.

Royal Bank of Canada first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $695K in Q4 2017. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Royal Bank of Canada held 4,519 shares of SANGAMO THERAPEUTICS INC worth $1K as of Q1 2026.
  • Royal Bank of Canada bought 414 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $165.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6945 holding.
  • Royal Bank of Canada first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's SANGAMO THERAPEUTICS INC position peaked at $695K in Q4 2017.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.